scholarly journals Orthotopic human melanoma xenograft model systems for studies of tumour angiogenesis, pathophysiology, treatment sensitivity and metastatic pattern

1994 ◽  
Vol 70 (5) ◽  
pp. 804-812 ◽  
Author(s):  
EK Rofstad
Keyword(s):  
Xenograft Model ◽  
Human Melanoma ◽  
Model Systems ◽  
Tumour Angiogenesis ◽  
Metastatic Pattern ◽  
Human Melanoma Xenograft ◽  
Melanoma Xenograft ◽  
Treatment Sensitivity

scholarly journals Anti-tumor activity of a combination of plasminogen activator and captopril in a human melanoma xenograft model

2004 ◽  
Vol 112 (2) ◽  
pp. 329-334 ◽  
Author(s):  
Renate R.J. de Groot-Besseling ◽  
Theo J.M. Ruers ◽  
Annemieke A. van Kraats ◽  
Geert J.M. Poelen ◽  
Dirk J. Ruiter ◽  
...  
Keyword(s):  
Plasminogen Activator ◽  
Xenograft Model ◽  
Human Melanoma ◽  
Human Melanoma Xenograft ◽  
Melanoma Xenograft ◽  
Anti Tumor Activity

scholarly journals Antibody Directed against Human YKL-40 Increases Tumor Volume in a Human Melanoma Xenograft Model in Scid Mice

PLoS ONE ◽  
2014 ◽  
Vol 9 (4) ◽  
pp. e95822 ◽  
Author(s):  
Johannes Salamon ◽  
Tatjana Hoffmann ◽  
Eva Elies ◽  
Kersten Peldschus ◽  
Julia S. Johansen ◽  
...  
Keyword(s):  
Tumor Volume ◽  
Xenograft Model ◽  
Human Melanoma ◽  
Scid Mice ◽  
Human Melanoma Xenograft ◽  
Melanoma Xenograft

scholarly journals Long-term efficiency of mesenchymal stromal cell-mediated CD-MSC/5FC therapy in human melanoma xenograft model

Gene Therapy ◽  
2014 ◽  
Vol 21 (10) ◽  
pp. 874-887 ◽  
Author(s):  
L Kucerova ◽  
S Skolekova ◽  
L Demkova ◽  
R Bohovic ◽  
M Matuskova
Keyword(s):  
Mesenchymal Stromal Cell ◽  
Stromal Cell ◽  
Xenograft Model ◽  
Human Melanoma ◽  
Human Melanoma Xenograft ◽  
Melanoma Xenograft

TNF-α downregulates vascular endothelial Flk-1 expression in human melanoma xenograft model

2003 ◽  
Vol 284 (1) ◽  
pp. H317-H329 ◽  
Author(s):  
Chandrakala Menon ◽  
Malini Iyer ◽  
Indira Prabakaran ◽  
Robert J. Canter ◽  
Shannon C. Lehr ◽  
...  
Keyword(s):  
Antitumor Activity ◽  
Fetal Liver ◽  
Xenograft Model ◽  
Tumor Vasculature ◽  
Human Melanoma ◽  
High Dose ◽  
Vegf Receptor ◽  
Tumor Endothelium ◽  
Human Melanoma Xenograft ◽  
Melanoma Xenograft

High-dose TNF with melphalan has significant antitumor activity in regional perfusion of the limbs and liver in human malignancies. TNF is believed to target tumor vasculature, but the precise molecular mechanism is unknown. The present study demonstrates that TNF downregulates the VEGF receptor, fetal liver kinase-1 (Flk-1), on tumor endothelium in a human melanoma xenograft model. NIH1286 human melanoma cells were transduced with a 720-bp fragment of the human VEGF121 gene to develop well-vascularized tumors that served as an amplified system for measuring Flk-1 expression changes. We injected 5 × 106 cells subcutaneously, each of two distinct single cell clones (NIH1286/3 and NIH1286/15), into athymic nude mice to produce tumors ∼10 mm in size. Each animal then received either BSA or TNF in BSA by tail vein. Tumors harvested at different time points post-TNF were analyzed for Flk-1 mRNA and protein expression. Data obtained showed that intravascular TNF downregulated Flk-1 expression in tumor endothelial cells. This effect could contribute to the antitumor activity of TNF known to target tumor vasculature.

scholarly journals Circulating miRNAs in Small Extracellular Vesicles Secreted by a Human Melanoma Xenograft in Mouse Brains

Cancers ◽  
2020 ◽  
Vol 12 (6) ◽  
pp. 1635
Author(s):  
Loredana Guglielmi ◽  
Marta Nardella ◽  
Carla Musa ◽  
Ingrid Cifola ◽  
Manuela Porru ◽  
...  
Keyword(s):  
Brain Metastasis ◽  
Extracellular Vesicles ◽  
Xenograft Model ◽  
Melanoma Cells ◽  
Human Melanoma ◽  
Circulating Mirnas ◽  
Human Melanoma Xenograft ◽  
Melanoma Xenograft ◽  
Melanoma Patients ◽  
The Brain

The identification of liquid biomarkers remains a major challenge to improve the diagnosis of melanoma patients with brain metastases. Circulating miRNAs packaged into tumor-secreted small extracellular vesicles (sEVs) contribute to tumor progression. To investigate the release of tumor-secreted miRNAs by brain metastasis, we developed a xenograft model where human metastatic melanoma cells were injected intracranially in nude mice. The comprehensive profiles of both free miRNAs and those packaged in sEVs secreted by the melanoma cells in the plasma demonstrated that most (80%) of the sEV-associated miRNAs were also present in serum EVs from a cohort of metastatic melanomas, included in a publicly available dataset. Remarkably, among them, we found three miRNAs (miR-224-5p, miR-130a-3p and miR-21-5p) in sEVs showing a trend of upregulation during melanoma progression. Our model is proven to be valuable for identifying miRNAs in EVs that are unequivocally secreted by melanoma cells in the brain and could be associated to disease progression.

Acidosis plus melphalan induces nitric oxide-mediated tumor regression in an isolated limb perfusion human melanoma xenograft model

Surgery ◽  
2002 ◽  
Vol 132 (2) ◽  
pp. 252-258 ◽  
Author(s):  
Scott T. Kelley ◽  
Chandrakala Menon ◽  
Donald G. Buerk ◽  
Todd W. Bauer ◽  
Douglas L. Fraker
Keyword(s):  
Nitric Oxide ◽  
Tumor Regression ◽  
Xenograft Model ◽  
Human Melanoma ◽  
Isolated Limb Perfusion ◽  
Limb Perfusion ◽  
Human Melanoma Xenograft ◽  
Melanoma Xenograft

scholarly journals Anti-Tumor Efficacy of PD-L1 Targeted Alpha-Particle Therapy in a Human Melanoma Xenograft Model

Cancers ◽  
2021 ◽  
Vol 13 (6) ◽  
pp. 1256
Author(s):  
Marisa Capitao ◽  
Justine Perrin ◽  
Sylvain Simon ◽  
Sébastien Gouard ◽  
Nicolas Chouin ◽  
...  
Keyword(s):  
Alpha Particle ◽  
Xenograft Model ◽  
Human Melanoma ◽  
Particle Therapy ◽  
Melanoma Tumor ◽  
Specific Tumor ◽  
Human Melanoma Xenograft ◽  
Melanoma Xenograft ◽  
New Treatment ◽  
Immunosuppressive Cells

PD-L1 (programmed death-ligand 1, B7-H1, CD274), the ligand for PD-1 inhibitory receptor, is expressed on various tumors, and its expression is correlated with a poor prognosis in melanoma. Anti-PD-L1 mAbs have been developed along with anti-CTLA-4 and anti-PD-1 antibodies for immune checkpoint inhibitor (ICI) therapy, and anti-PD-1 mAbs are now used as first line treatment in melanoma. However, many patients do not respond to ICI therapies, and therefore new treatment alternatives should be developed. Because of its expression on the tumor cells and on immunosuppressive cells within the tumor microenvironment, PD-L1 represents an interesting target for targeted alpha-particle therapy (TAT). We developed a TAT approach in a human melanoma xenograft model that stably expresses PD-L1 using a 213Bi-anti-human-PD-L1 mAb. Unlike treatment with unlabeled anti-human-PD-L1 mAb, TAT targeting PD-L1 significantly delayed melanoma tumor growth and improved animal survival. A slight decrease in platelets was observed, but no toxicity on red blood cells, bone marrow, liver or kidney was induced. Anti-tumor efficacy was associated with specific tumor targeting since no therapeutic effect was observed in animals bearing PD-L1 negative melanoma tumors. This study demonstrates that anti-PD-L1 antibodies may be used efficiently for TAT treatment in melanoma.

Sign in / Sign up

Export Citation Format

Share Document